Last edition
News about "infigratinib NDA acceptance"
US FDA Accepts BridgeBio's Infigratinib NDA for Achondroplasia
BridgeBio has announced the US FDA acceptance and Priority Review (PR) of New Drug Application (NDA) for oral infigratinib for children with achondroplasia.
Infigratinib NDA Acceptance | 08/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members